A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Phase 1

Not yet recruiting

• Conditions: Non Small Cell Lung Cancer
• Interventions: Drug: DZD6008

• Registration Number: NCT06905197
• Lead Sponsor: Dizal Pharmaceuticals

Brief Summary

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Detailed Description

The study includes two parts: Part A (dose escalation) and Part B(dose expansion). In Part A, locally advanced or metastatic NSCLC patients with EGFR sensitizing mutations (Exon19del and/or L858R) following at least 1 prior EGFR TKI regimen will be enrolled. In Part B, locally advanced or metastatic NSCLC patients with EGFR sensitizing mutations following at least 1 prior EGFR TKI treatment and harboring C797X mutation will be enrolled.

Study Timeline

• Status Verified: 2025-03
• Study First Submitted: 2025-03-25
• Study First Submitted QC: 2025-03-25
• Last Update Submitted: 2025-03-25
• Study First Posted: 2025-04-01
• Last Update Posted: 2025-04-01
• Study Start: 2025-06
• Primary Completion: 2027-09
• Study Completion: 2028-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

1. Patients must be able to provide documented informed consent.
2. Aged ≥ 18 years.
3. Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced or metastatic, not suitable for curative therapy.
4. Documentation of EGFR mutations from a local CLIA-certified laboratory (or equivalent). Part A: EGFR sensitizing mutations (Exon19del and/or L858R). Part B: EGFR sensitizing mutations (Exon19del and/or L858R) and C797X mutation.
5. Provide adequate amount of pretreatment tumor samples collected after disease progression on the last EGFR TKI treatment.
6. Failed (progressed or are intolerant) from at least 1 prior EGFR TKI regimen.
7. ECOG 0 or 1 with predicted life expectancy ≥ 12 weeks.
8. Patients with brain metastases must have a stable BM status.
9. Measurable disease per RECIST 1.1.
10. Adequate hematopoietic and other organ system functions.
11. Male Patients with female partners of childbearing potential should use barrier contraceptives and refrain from donating sperm during their participation in this study and for 3 months following the last dose of the study drug.

Exclusion Criteria

1. Carry any other known EGFR alterations, including but not limited to uncommon EGFR mutations (G719X, S768I, L861Q, exon 20 insertions, etc.)(Part B).
2. NSCLC with mixed small cell lung cancer (SCLC) or NSCLC with histologic SCLC transformation.
3. Prior treatment with any of the following: 1)Immunotherapy or other antibody therapy within 4 weeks prior to the first administration; 2)Any cytotoxic chemotherapy, investigational drugs or other anticancer drugs from a previous treatment regimen or clinical study within 14 days prior to the first administration; 3)Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose, radiation to more than 30% of the bone marrow or with a wide field of radiation within 28 days before screening; 4)Currently receiving or unable to stop drug or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 (CYP)3A4. A washout period of at least 2 weeks for strong inhibitors and 3 weeks for strong inducers is required prior to the first study drug administration; 5)currently receiving or unable to stop drugs known to be CYP3A4 sensitive substrate with a narrow therapeutic index. A washout period of at least 14 days is required prior to the first study drug administration; 6)currently receiving or unable to stop drugs known to be proton pump inhibitors. A washout period of at least 7 days is required prior to the first study drug administration; 7)major surgery within 4 weeks of the first administration of DZD6008 or anticipated during the study period.
4. Any unresolved toxicities from prior anti-cancer therapy greater than CTCAE Grade 1.
5. Spinal cord compression or leptomeningeal metastasis.
6. Patients with any other malignancy within 2 years of the first administration of study drug.
7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses as judged by investigator.
8. Patients with active infection, including but not limited to HBV, HCV, HIV and active infection of COVID-19.
9. Resting QTcF > 470 msec; Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG;Any factors that increase the risk of QTc prolongation.
10. Past medical history of ILD or active ILD.
11. Diseases which would preclude adequate absorption of DZD6008.
12. Received a live vaccine within 2 weeks before the first administration of DZD6008.
13. Women who are pregnant or breastfeeding.
14. Hypersensitivity to active or inactive excipients of DZD6008.
15. Involvement in the planning and conduct of the study.
16. Judgment by the investigator that the patient is unlikely to comply with study procedures

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Experimental: Part A Dose Escalation cohorts (20 mg once daily [QD])	DZD6008	-
Experimental: Part A Dose Escalation cohorts (40 mg QD)	DZD6008	-
Experimental: Part A Dose Escalation cohorts (60 mg QD)	DZD6008	-
Experimental: Part A Dose Escalation cohorts (90 mg QD)	DZD6008	-
Experimental: Part A Dose Escalation cohorts (120 mg QD)	DZD6008	-
Experimental: Part A Dose Escalation cohorts (150 mg QD)	DZD6008	-
Experimental: Part B Dose Expansion cohorts (selected dose 1 QD)	DZD6008	-
Experimental: Part B Dose Expansion cohorts (selected dose 2 QD)	DZD6008	-

Primary Outcome Measures

Name	Time	Method
Part A: To assess safety and tolerability	Through the study completion, an average of around 1 year	Number of participants with Adverse events (AEs)/Serious adverse events (SAEs)
Part B: To assess anti-tumor activity	Through the study completion, an average of around 1 year	Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Secondary Outcome Measures

Name	Time	Method
Part A: To characterize the plasma concentration of DZD6008 following single and multiple oral dose administration	From first dosing to cycle 7 day 1, each cycle is 21 days	Total concentrations of DZD6008 in plasma
Part A: To assess the anti-tumor activity	Through the study completion, an average of around 1 year	Progression Free Survival (PFS) assessed by investigators per RECIST version 1.1
Part B: To assess the anti-tumor activity	PFS assessed by IRC and investigators per RECIST version 1.1	Through the study completion, an average of around 1 year
Part B: Plasma concentration of DZD6008	Time Frame: From first dosing to cycle 11 day 1, each cycle is 21 days	Total concentrations of DZD6008 in plasma
Part B: To assess safety and tolerability	Through the study completion, an average of around 1 year	Number of participants with AEs/SAEs

Trial Locations

Locations (1)

Herbert Irving Comprehensive Cancer Center; 🇺🇸 New York, New York, United States